publications-banner

Information about pipeline products

PublicationView

Valemetostat
Lung Cancer
A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer
Choudhury NJ, Lai WV, Makhnin A, et al.
Clin Cancer Res. 2024;30(17):3697-3703. doi: 10.1158/1078-0432.CCR-23-3383.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: Subgroup analysis of the DESTINY-Breast04 study
Yamashita T, Sohn JH, Tokunaga E, et al.
Breast Cancer. 2024;31(5):858-868. doi: 10.1007/s12282-024-01600-7.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: Long-term survival analysis of the DESTINY-Breast03 trial
Cortés J, Hurvitz SA, Im S-A, et al.
Nat Med. 2024;30(8):2208-2215. doi: 10.1038/s41591-024-03021-7.
T-DXd
Gastric Cancer
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: Exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial
Shitara K, Bang Y-J, Iwasa S, et al.
Nat Med. 2024;30(7):1933-1942. doi: 10.1038/s41591-024-02992-x.
Dato-DXd
Breast Cancer
Datopotamab deruxtecan in advanced or metastatic HR+/HER2- and triple-negative breast cancer: Results from the phase I TROPION-PanTumor01 study
Bardia A, Krop IE, Kogawa T, et al.
J Clin Oncol. 2024;42(19):2281-2294. doi: 10.1200/JCO.23.01909. Epub 2024 Apr 2
T-DXd
Breast Cancer
Global study on the accuracy of human epidermal growth factor receptor 2-low diagnosis in breast cancer
Rüschoff J, Penner A, Ellis IO, et al.
Arch Pathol Lab Med. 2024. doi: 10.5858/arpa.2024-0052-OA. Epub ahead of print.
T-DXd
Colorectal Cancer
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): Primary results from a multicentre, randomised, phase 2 trial
Raghav K, Siena S, Takashima A, et al.
T-DXd
Other/Multi Tumor-agnostic
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): A multicenter, single-arm, phase II trial
Ohba A, Morizane C, Kawamoto Y, et al.
J Clin Oncol. 2024:JCO2302010. doi: 10.1200/JCO.23.02010. Epub ahead of print.
HER3-DXd
Lung Cancer
Real-world treatment patterns and clinical outcomes among patients with metastatic or unresectable EGFR-mutated non-small cell lung cancer previously treated with osimertinib and platinum-based chemotherapy
Patel J, Meng J, Le H, et al.
Adv Ther. 2024;41(8):3299-3315. doi: 10.1007/s12325-024-02936-4.
Valemetostat
Other/Multi Tumor-agnostic
Population pharmacokinetics of total and unbound valemetostat and platelet dynamics in healthy volunteers and patients with non-Hodgkin lymphoma
Fukae M, Baron K, Tachibana M, et al.
CPT Pharmacometrics Syst Pharmacol. 2024. doi: 10.1002/psp4.13201. Epub ahead of print.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer